Browse FABP1

Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain -
Function

Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes (PubMed:25732850). Binds cholesterol (PubMed:25732850). Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport (By similarity).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001666 response to hypoxia
GO:0006631 fatty acid metabolic process
GO:0006635 fatty acid beta-oxidation
GO:0006638 neutral lipid metabolic process
GO:0006639 acylglycerol metabolic process
GO:0006641 triglyceride metabolic process
GO:0006820 anion transport
GO:0006869 lipid transport
GO:0006979 response to oxidative stress
GO:0007586 digestion
GO:0009062 fatty acid catabolic process
GO:0009636 response to toxic substance
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010035 response to inorganic substance
GO:0010466 negative regulation of peptidase activity
GO:0010565 regulation of cellular ketone metabolic process
GO:0010876 lipid localization
GO:0010951 negative regulation of endopeptidase activity
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0016042 lipid catabolic process
GO:0016054 organic acid catabolic process
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0019395 fatty acid oxidation
GO:0019433 triglyceride catabolic process
GO:0022600 digestive system process
GO:0030258 lipid modification
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031998 regulation of fatty acid beta-oxidation
GO:0032000 positive regulation of fatty acid beta-oxidation
GO:0034440 lipid oxidation
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0042180 cellular ketone metabolic process
GO:0042542 response to hydrogen peroxide
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0044242 cellular lipid catabolic process
GO:0044282 small molecule catabolic process
GO:0045834 positive regulation of lipid metabolic process
GO:0045861 negative regulation of proteolysis
GO:0045923 positive regulation of fatty acid metabolic process
GO:0046320 regulation of fatty acid oxidation
GO:0046321 positive regulation of fatty acid oxidation
GO:0046395 carboxylic acid catabolic process
GO:0046461 neutral lipid catabolic process
GO:0046464 acylglycerol catabolic process
GO:0046486 glycerolipid metabolic process
GO:0046503 glycerolipid catabolic process
GO:0046942 carboxylic acid transport
GO:0050892 intestinal absorption
GO:0050994 regulation of lipid catabolic process
GO:0050996 positive regulation of lipid catabolic process
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0070301 cellular response to hydrogen peroxide
GO:0070482 response to oxygen levels
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0072329 monocarboxylic acid catabolic process
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1990748 cellular detoxification
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
Molecular Function GO:0003682 chromatin binding
GO:0005319 lipid transporter activity
GO:0005324 long-chain fatty acid transporter activity
GO:0005496 steroid binding
GO:0005504 fatty acid binding
GO:0005543 phospholipid binding
GO:0008144 drug binding
GO:0015245 fatty acid transporter activity
GO:0016209 antioxidant activity
GO:0031406 carboxylic acid binding
GO:0032052 bile acid binding
GO:0033293 monocarboxylic acid binding
GO:0043168 anion binding
Cellular Component GO:0005777 peroxisome
GO:0005782 peroxisomal matrix
GO:0005938 cell cortex
GO:0031907 microbody lumen
GO:0042579 microbody
GO:0044438 microbody part
GO:0044439 peroxisomal part
GO:0044448 cell cortex part
GO:0045177 apical part of cell
GO:0045179 apical cortex
GO:0099568 cytoplasmic region
GO:0099738 cell cortex region
> KEGG and Reactome Pathway
 
KEGG hsa03320 PPAR signaling pathway
hsa04975 Fat digestion and absorption
Reactome R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-163560: Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FABP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FABP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27687006Colorectal CarcinomaInhibit immunity (infiltration)Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway. Previously, we compared expression of colonic epithelium genes in a subset of microsatellite instable (MSI) colorectal carcinomas (medullary carcinomas) to normal colonic mucosa and found that FABP1 expression was markedly decreased in the tumors. FABP1 was preferentially lost in MSI carcinomas (123/133, 93%) compared with microsatellite stable carcinomas (240/562, 43%, P<0.0001). In addition, higher numbers of tumor-infiltrating lymphocytes were present in tumors with loss of FABP1 (P<0.0001). Decreased expression of the fatty acid storage and glucose regulator, PPARγ, was associated with the loss of FABP1 (P<0.0001).
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FABP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FABP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.3150.179
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0880.955
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.3690.0679
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2150.832
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2710.374
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.0790.233
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1640.885
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1820.929
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0460.982
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 483.1240.192
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 285.6730.061
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1010.78
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FABP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FABP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FABP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FABP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FABP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FABP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FABP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFABP1
Namefatty acid binding protein 1, liver
Aliases L-FABP; FABPL; fatty acid-binding protein 1; liver-type fatty acid-binding protein; Fatty acid-binding prote ......
Chromosomal Location2p11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FABP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.